The newly approved Edwards Lifesciences Sapien 3 aortic valve

July 5, 2015- Interviewed by Steven E. Greer, MD

We interviewed William Suh, MD of UCLA about the newly approved Edwards Lifesciences Sapien 3 aortic valve. Read more »

Review of the TAVR data from the 2015 ACC

May 7, 2015- Interviewed by Steven E. Greer, MD

Vagal nerve stimulation for weight loss

January 22, 2015- Interviewed by Steven E. Greer, MD

Erik Dutson, MD, bariatric surgeon from UCLA, Read more »

Current surgical weight loss therapies

January 24, 2014- Interviewed by Steven E. Greer, MD

Erik Dutson, MD, weight loss surgeon at UCLA, explains why his medical center does not implant the Lap-Band, and how the “sleeve” bypass is the main procedure of choice now for weight loss surgery.

Antoni Ribas, MD discusses cancer drugs targeting the PD1 signaling pathways

Interviewed by Steven E. Greer, MD

March 19, 2013

The upcoming ASCO meeting will be dominated by numerous presentations relating to new cancer drugs targeting the cell surface molecule called PD-L1, and the immune cell receptors PD1. Early Phase 1 data in non-small cell lung cancer, renal cancer, and melanoma demonstrated such impressive sustained tumor responses that they papers were published in the New England Journal of Medicine. Antoni Ribas, MD of the UCLA Jonsson Comprehensive Cancer Center is involved in trials testing some of these new molecules. In the video interview, he explains the mechanisms of action, reviews data published so far, and previews new data to be seen at ASCO.

Phase 3 data on BRAF and MEK combos for melanoma

Interviewed by Steven E. Greer, MD

We have previously reported on Phase 2 data indicating that the combination of a BRAF and MEK inhibitor drug Read more »

The Daltrey Townshend teenage and young adult cancer center at UCLA

More than 20 years ago, Roger Daltrey began forming special cancer units in the UK to treat patients in their teenage and young adult years. Now, with the other member of the legendary rock band The Who, Pete Townshend, they have formed the UCLA Daltrey/Townshend cancer center and are planning more in the united states. We had the honor to be granted a rare interview with Mr. Daltrey.

Drug-coated balloons to treat fem-pop disease

April 27, 2014- Interviewed by Steven E. Greer, MD

At the Charing Cross symposium in London, Medtronic reported results of the IN-PACT trial of their paclitaxel balloon. 12-month patency rates were 82%, compared to Read more »

Interview with Simon Townshend about the Daltrey/Townshend Teen Cancer Program

The Daltrey Townshend teenage and young adult cancer center at UCLA

New therapies for hepatitis C

Interviewed by Steven E. Greer, MD

In Part 1, Sammy Saab, MD, MPH, liver disease and GI doctor from UCLA, discusses the standard of care for hepatitis C, which is 48-weeks of interferon with ribavirin. He then discusses the new protease inhibitor drugs, Incivek and Victrelis, and why their bad side effect profile limited usage despite higher cure rates.

In Part 2, Dr. Saab discusses the data on the new all-oral therapies that do not require the toxic interferon injections, are only 12-weeks of therapy, and have much higher cure rates approaching 100% SVR. He mentions Gilead’s sofosbuvir, the Abbvie cocktail of drugs, and others.